MedRise Medical News

White House Presses 17 Drugmakers on Medicaid Prices as HHS Relaunches HealthData.gov

The White House sent letters to the chief executives of 17 drugmakers on July 31, 2025, giving them until September 29 to commit to most-favored-nation prices, the lowest paid in other developed countries, for every Medicaid patient, Manatt's analysis of the letters shows.

A day earlier, HHS relaunched HealthData.gov with more than three times as many public datasets. One story is about what medicines cost. The other is about the data anyone can now use to study it.

Four demands and a deadline

The letters asked each company to:

  1. Extend most-favored-nation pricing to Medicaid.
  2. Commit to those prices on newly launched drugs for Medicare, Medicaid and commercial payers.
  3. Negotiate harder with other countries and return the extra revenue to lower U.S. prices.
  4. Sell directly to patients or businesses at most-favored-nation prices.

The recipients were AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi, BioPharm International reported. The letters warned the administration would use “every tool in our arsenal” if companies did not act.

How the industry and markets reacted

The S&P 500 Pharmaceuticals Index fell 2.7% that day, Bloomberg reported. PhRMA spokesman Alex Schriver said, “Importing foreign price controls would undermine American leadership.”

What happened next

The White House has since announced pricing agreements with drugmakers, including nine more in August 2026, and launched TrumpRx.gov on February 5, 2026, according to a White House fact sheet.

HealthData.gov: from about 3,000 datasets to more than 10,000

On July 30, 2025, HHS announced that HealthData.gov had grown from about 3,000 datasets in January 2025 to more than 10,000. It published version 1.0 of an HHS Open Data Plan, a Metadata Standard and a Data Inventory, and added search tools, APIs and dashboards. HHS Chief Data Officer Dr. Kristen Honey called open data the “foundation for radical transparency, innovation, accountability, and public trust.”

Why it matters for students and residents

  • Medicaid patients feel drug prices first. Cost shapes which prescriptions get filled. Ask about coverage before you choose between equivalent drugs.
  • Free data for your research. HealthData.gov is a starting point for quality improvement and research projects. Our research course walks through the basics.

Prices are being negotiated in letters and deals. The data to judge the results is public. More in MedRise Medical News.

Sources: Manatt; BioPharm International; Bloomberg via SupplyChainBrain; White House, August 2026; HHS, July 30, 2025.

MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.